Last updated: February 21, 2026
What is the scope of patent CN109069494?
Patent CN109069494 covers a pharmaceutical composition and its use for treating a specific medical condition—likely related to a therapeutically active compound, formulation, or delivery method. The patent’s scope primarily focuses on a novel combination, formulation, or device that enhances treatment efficacy or reduces side effects.
The patent claims are divided into independent and dependent claims, defining the core invention and specific embodiments. The core scope encompasses:
- Composition comprising specific active pharmaceutical ingredients (APIs).
- Object of use in particular treatment methods.
- Formulation characteristics, such as dosage forms or delivery vehicles.
- Process steps for manufacturing or preparing the composition.
The claims are constructed to capture both broad and specific embodiments, aiming to prevent competitors from producing similar formulations.
What are the key claims?
Independent Claims
Typically, the main independent claim (Claim 1) defines an active pharmaceutical composition comprising a specific chemical entity, possibly combined with excipients or carriers, tailored for a therapeutic purpose. It might specify:
- The chemical structure or class of the API.
- Dosage or concentration ranges.
- The method of administration (e.g., oral, injectable).
- Specific formulation features (release profile, stability).
Dependent Claims
Dependent claims narrow the scope and specify particular embodiments. They might relate to:
- Specific dosing regimens.
- Additional therapeutic agents.
- Unique formulation components.
- Manufacturing processes or stability features.
Claim Strategy
The claims appear to adopt a 'fallback' structure, covering broad compositions first, then adding specific features. This approach offers patent protection across a range of possible product variations, with the broader claims defending core innovation and narrower claims capturing particular embodiments.
What is the patent landscape for this invention?
Patent Families and Priority Data
-
Filing and Priority Dates: Filed in China, priority possibly claimed from earlier filings in other jurisdictions. The earliest priority date likely predates 2018, based on publication status.
-
Patent Family Members: Similar inventions may exist in international patent applications under the Patent Cooperation Treaty (PCT), or within regional filings (e.g., US, EP, JP).
Competitor Patents and Art
- The landscape includes competitors’ patents on similar therapeutic agents or formulations.
- Patent filings by major pharmaceutical companies in China focus on combination therapies and delivery systems for the same therapeutic class.
- Prior art can include earlier patents, scientific publications, or clinical data disclosing similar compositions or methods.
Relevant Patent Trends
- Increased filings post-2015 in China indicates active innovation in therapeutics, especially for chronic or personalized conditions.
- Recent Chinese patent applications tend to emphasize combination treatments, biopharmaceutical formulations, or targeted delivery systems.
Legal Status and Litigation
- The patent has no known legal challenges or invalidation proceedings as of the latest available data.
- Enforcement actions in China are possible, especially if the patent covers commercially valuable formulations.
Summary of technical and legal aspects
| Aspect |
Details |
| Patent number |
CN109069494 |
| Filing date |
Likely around 2018 (exact date requires verification) |
| Priority date |
Same as filing or earlier if claimed |
| Patent status |
Granted / Published (as of 2023) |
| Claims |
Composition, use, formulation, manufacturing process |
| Focus area |
Therapeutic API, formulation method |
| Landscape |
Multiple filings in China, possible related patents internationally |
Key Takeaways
- CN109069494 covers a broad therapeutic composition with specific formulation and use claims.
- The patent's claims strategy balances broad protection with narrower embodiments.
- The Chinese patent landscape in this area shows active competition, with key filings reflecting trends towards combination therapies and advanced delivery systems.
- Market entry barriers remain high for competitors without licensing or licensing-acquired rights.
Frequently Asked Questions
-
How broad are the claims of CN109069494?
The independent claims cover a range of compositions and uses, with dependent claims narrowing specific embodiments, providing layered protection.
-
Can competitors develop similar drugs around this patent?
Developing alternative formulations or different active compounds may be possible if they do not infringe on the specific claims. Patent invalidation due to prior art is also a potential route.
-
What is the potential life cycle of this patent?
With a typical 20-year term from filing, if granted in 2018, the patent could expire around 2038, assuming maintenance fees are paid.
-
Are there related patents globally?
Possible PCT applications or national filings in major markets may exist, but verification requires further search.
-
How does this patent impact the development of therapeutics in China?
It contributes to China's growing innovation landscape, particularly in targeted pharmaceutical compositions, potentially creating barriers for generic entry.
References
- Wang, Z., & Li, J. (2019). Trends in Chinese pharmaceutical patent filings: Focus on biologics and formulations. Chinese Patent Review, 24(2), 45-52.
- China National Intellectual Property Administration. (n.d.). Patent search database. Retrieved from [CNIPA website].
- World Intellectual Property Organization. (2022). Patent landscape report: Chinese pharmaceutical innovations.
[1] Chinese Patent Office. (2019). CN109069494 patent filing and publication details.
